COCP News

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

(NASDAQ:COCP) BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time.

September 3, 2025Investor Conference

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

COCP

BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and six months ended June 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.

August 14, 2025Earnings

Cocrystal Pharma's Recent Virology Study Shows Broad-Spectrum Influenza PB2 Inhibitor CC-42344 Exhibits Strong Antiviral Activity Against Highly Pathogenic H5N1 Avian Influenza A Strain

COCP

May 29, 2025

Cocrystal Pharma Q1 EPS $(0.23) Beats $(0.51) Estimate

COCP

May 15, 2025

Cocrystal Pharma Announces Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against The Emerging GII.17 Variants

COCP

April 24, 2025